Jason Kelly
Emerging from stealth, Octant is bringing the tools of synthetic biology to large scale drug discovery
Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery. As the pharmaceuti
Ginkgo Bioworks’ dev shop for genetic programming is now worth $4 billion
Ginkgo Bioworks is now worth $4 billion after a $290 million capital infusion that will give the company the cash to dramatically expand its developer shop for genetic programming. The Boston-based co
Biotech researchers venture into the wild to start their own business
Much of Silicon Valley mythology is centered on the founder-as-hero narrative. But historically, scientific founders leading the charge for bio companies have been far less common.
Ginkgo Bioworks secures $275 million in Series D, valuing the company at over $1 billion
Boston biotech startup Ginkgo Bioworks has announced the raise of $275 million in Series D funding to build out its Bioworks3 production facility. The funding comes from previous investors Viking Glo